Blackstone, Bain Capital and Taisho Pharmaceutical are among the final bidders for Takeda Pharmaceutical’s consumer drug business in Japan, a deal that could be worth up to 400 billion yen ($3.7 billion), three people familiar with the deal said.
Japan’s Taisho Pharmaceutical Holdings Co Ltd is the front runner for the deal, all three people said. CVC Capital Partners is also among the final bidders, they said.
